BIOGEN INC. - COMMON STOCK

Two-Year Real-World Study of LEQEMBI® in the United States Presented at Alzheimer's Association International Conference (AAIC) 2025

30 Jul 2025 10:00:00 By Nasdaq GlobeNewswire

ZURZUVAE® (zuranolone) Receives Positive Opinion from CHMP for the Treatment of Women with Postpartum Depression

25 Jul 2025 06:20:26 By Nasdaq GlobeNewswire

Biogen to Highlight Scientific Progress Across Alzheimer’s Disease at the Alzheimer’s Association International Conference 2025

21 Jul 2025 18:30:00 By Nasdaq GlobeNewswire

Biogen Announces $2 Billion Manufacturing Investment in North Carolina’s Research Triangle Park in Conjunction with its 30th Anniversary

21 Jul 2025 06:30:00 By Nasdaq GlobeNewswire

Biogen and Stoke Therapeutics Announce Presentation of Data from Studies of Zorevunersen, an Investigational Medicine for Dravet syndrome, at the 16th European Paediatric Neurology Society (EPNS) Congress

10 Jul 2025 06:00:00 By Nasdaq GlobeNewswire

Biogen Initiates Phase 3 Study of Felzartamab for the Treatment of Primary Membranous Nephropathy

30 Jun 2025 06:30:12 By Nasdaq GlobeNewswire

New Data for Nusinersen Underscore Biogen’s Commitment to Advancing Clinical Research to Improve Outcomes in SMA

27 Jun 2025 09:00:23 By Nasdaq GlobeNewswire

Biogen to Advance Investigational Spinal Muscular Atrophy Asset to Registrational Studies Based on Positive Interim Phase 1 Results

25 Jun 2025 06:30:37 By Nasdaq GlobeNewswire

Biogen Initiates Phase 3 Pediatric Study of Omaveloxolone for the Treatment of Friedreich Ataxia

18 Jun 2025 06:30:27 By Nasdaq GlobeNewswire

Dapirolizumab Pegol Phase 3 Data in SLE Presented at the Annual European Congress of Rheumatology (EULAR) Show Improvement in Fatigue and Reduction in Disease Activity

12 Jun 2025 00:00:39 By Nasdaq GlobeNewswire

Biogen and City Therapeutics Announce Strategic Research Collaboration to Develop Select Novel RNAi-based Therapies

27 May 2025 06:30:00 By Nasdaq GlobeNewswire

Leqembi®∇ (lecanemab) is the First Medicine that Slows Progression of Early Alzheimer’s Disease to be Authorized in the European Union

15 Apr 2025 18:00:00 By Nasdaq GlobeNewswire

NetDania - New 12 months Low: BIOGEN INC. - COMMON STOCK

09 Apr 2025 08:45:15 By NetDania Notify

NetDania - New 12 months Low: BIOGEN INC. - COMMON STOCK

08 Apr 2025 12:06:04 By NetDania Notify

NetDania - New 12 months Low: BIOGEN INC. - COMMON STOCK

07 Apr 2025 08:45:03 By NetDania Notify

NetDania - New 12 months Low: BIOGEN INC. - COMMON STOCK

04 Apr 2025 08:47:36 By NetDania Notify

Biogen’s Investigational Tau-Targeting Therapy BIIB080 Receives FDA Fast Track Designation for the Treatment of Alzheimer’s Disease

02 Apr 2025 06:30:00 By Nasdaq GlobeNewswire

Biogen Announces Plans for New Global Headquarters and Innovation Hub in Kendall Square

24 Mar 2025 06:30:00 By Nasdaq GlobeNewswire

Biogen Initiates Phase 3 Study of Felzartamab for the Treatment of Late Antibody-Mediated Rejection (AMR) in Kidney Transplant Patients

11 Mar 2025 06:30:00 By Nasdaq GlobeNewswire

Biogen and Stoke Therapeutics Enter into Collaboration to Develop and Commercialize Zorevunersen for the Treatment of Dravet Syndrome, a Rare Genetic Epilepsy Associated with Refractory Seizures and Neurodevelopmental Impairments

18 Feb 2025 07:00:00 By Nasdaq GlobeNewswire